Quantcast Mohamed Industry News
mohamed industry news By
mohamed industry news >> CANCER March 05, 2015 members login here
>>  CANCER
Video: CNBC update: Lung cancer drug approved
NBCNews.com - 21 Hours ago
CNBC   |   March 04, 2015 Mexico arrests leader of Zetas drug cartel, Senate fails to override Obama's keystone veto and homeland security funding bill is signed, reports CNBC's Sue
     Add Comment

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated
CNBC - 21 Hours ago
Opdivo is the first and only immuno-oncology therapy proven to extend survival in patients treated with one prior therapy CheckMate -017 achieved the benchmark goal of improving overall survival
FDA Approves Opdivo (nivolumab) for the Treatment of Patients with ... Finwin
BRISTOL MYERS SQUIBB : FDA Approves Opdivo (nivolumab) for the Treatment of Patients 4 Traders
all 3 news articles >>      Add Comment

Could Oxygen Make Cancer Therapy Work Better?
NBCNews.com - 22 Hours ago
Researchers have been looking for years for a way to use oxygen to fight cancer. Now, they may finally have one. A new study finds that giving high-dose oxygen may help efforts to stimulate the immune
     Add Comment

Sun damage causes genetic changes that predispose children and adolescents to melanoma
Bloomberg - 22 Hours ago
/PRNewswire-USNewswire/ -- The St. Jude Children's Research Hospital""Washington University Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the
     Add Comment

US FDA approves Bristol-Myers immunotherapy for lung cancer
Reuters - 24 Hours ago
(Reuters) - U.S. health regulators on Wednesday approved Bristol-Myers Squibb Co's drug, Opdivo, which helps the immune system fight cancer, to treat squamous non-small cell lung cancer once the disease
U.S. FDA approves Bristol-Myers immunotherapy for lung cancer Reuters India
all 1 news articles >>      Add Comment

Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of
Reuters - 3/4/2015
(GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (Nasdaq:MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test
     Add Comment

No conclusive proof of mobile radiations causing cancer: ICMR study
Times of India - 21 Hours ago
NEW DELHI: A latest study by Indian Council of Medical Research (ICMR) said there is no conclusive data or evidence so far to show that radiations from mobile phone or towers have adverse health effects.
     Add Comment

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated
A.M. Best - 21 Hours ago
__
     Add Comment

Bristol-Myers Lung Cancer Drug Opdivo Wins Speedy OK
Investor's Business Daily - 22 Hours ago
T he Food and Drug Administration approved Bristol-Myers Squibb 's (NYSE: BMY ) PD-1 inhibitor Opdivo for squamous-cell lung cancer Wednesday, well ahead of the expected timeline. The stock jumped to
     Add Comment

Prognostic impact of hyponatraemia in patients with colorectal cancer
Journal of Colorectal Disease - 22 Hours ago
Abstract We read with interest the article by Chol et al presenting the negative impact on long term overall survival in patients with various degrees of hyponatraemia during hospitalisation following
     Add Comment

HNF1ß and S100A1 are useful biomarkers for distinguishing renal oncocytoma and chromophobe
Journal of Cancer Cytopathology - 22 Hours ago
BACKGROUND Morphologic overlap between renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC) can pose diagnostic challenges, especially in biopsy samples in which tumor quantity may be limited,
     Add Comment

First Immunotherapy for Lung Cancer Approved
American Journal of Public Health - 22 Hours ago
Nivolumab ( Opdivo , Bristol-Myers Squibb Company) is the first immunotherapy to be available for use in the treatment of lung cancer. The drug has just been approved by the US Food and Drug Administration
FDA Approves Opdivo, First Immunotherapy for Lung Cancer Diabetes Care
all 1 news articles >>      Add Comment

Edmonton EMS roll up sleeves for ongoing cancer study spanning 50 years
Metro Canada - 22 Hours ago
Rather than taking vitals on patients, Edmonton EMS rolled up their own sleeves Wednesday as they joined nearly 50,000 other Albertans to take part in a research study that will span half a century.
     Add Comment

FDA approves Bristol-Myers drug for lung cancer
Yahoo! Finance UK and Ireland - 23 Hours ago
The Food and Drug Administration on Wednesday expanded approval of an innovative Bristol-Myers Squibb drug to treat the most common form of lung cancer. Regulators cleared Opdivo for patients with advanced
     Add Comment

Lung Cancer Therapeutics Market - Size, Share, Trends Analysis and Global Industry
A.M. Best - 23 Hours ago
New York, NY -- (ReleaseWire) -- 03/04/2015 -- Cancer is a disease of genes which are caused due to abnormal growth of cells. These abnormal cells further migrate from the original site to other site
     Add Comment

3D Printing Offers Insights Into Cancer Development
Dermatology Online Journal - 23 Hours ago
Our understanding of the complexities of tumors and even radiotherapy delivery could soon be revolutionized through the use of 3D printing, claim researchers who are pioneering a number of groundbreaking
     Add Comment

The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval
Neuropsychopharmacology - 23 Hours ago
To read this article in full you may need to log in, make a payment or gain access through a site license (see right). Neuropsychopharmacology (11 February 2015) | doi :10.1038/npp.2015.48 Areg Barsegyan
An iGlu Receptor Antagonist and Its Simultaneous Use with an Anticancer Drug for Chemistry European Journal
all 1 news articles >>      Add Comment

Hearing Science: Our Ears May Be Able to Tell Cancer Cells from Healthy Ones and
Scientific American - 3/4/2015
Ears are such terrific pattern finders that scientists are using audio data to detect cancer cells and particles from space By Ron Cowen THIS IS A PREVIEW. or subscribe to access the full article.
     Add Comment

Bowel cancer patients are missing out on vital test
ITV.com - 3/4/2015
Bowel cancer patients could be missing out on the best treatment and outcomes because a vital test is not being used enough according to a report out today. A biomarker test is a way of identifying which
     Add Comment

Inaugural palliative care symposium focuses on improving field
Journal of Cancer - 3/4/2015
_
     Add Comment

NCI launches exceptional responders initiative: Researchers will attempt to identify
Journal of Cancer - 3/4/2015
_
     Add Comment

Issue information
Journal of Cancer - 3/4/2015
_
     Add Comment

Early estimates of SEER cancer incidence for 2012: Approaches, opportunities, and
Journal of Cancer - 3/4/2015
BACKGROUND The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program collects and publishes population-based cancer incidence data from registries covering approximately
     Add Comment

LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment
Green Technology - 3/4/2015
[March 04, 2015] Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate
     Add Comment

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
A.M. Best - 24 Hours ago
Dallas, TX -- (ReleaseWire) -- 03/04/2015 -- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H1 2015, provides an overview of the Hormone Refractory
Refining Industry Outlook in North America to 2019 - Capacity and Capital Expenditure Securities Technology Monitor
Refining Industry Outlook in Europe to 2019 - Capacity and Capital Expenditure Forecasts Securities Technology Monitor
all 16 news articles >>      Add Comment

Already a member? Sign in
Email Address:
Password:
Forget your password?

Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms of Use   |   Privacy Policy   |   Need Help?   |   Site Map
Copyright ©2015 Congoo.com. All Rights Reserved.